Nkarta, Inc. reported financial results for the second quarter ended June 30, 2026, reporting a net loss of $40.4 million, or $0.54 per share. Research and development expenses increased to $29.0 million from $20.8 million in the prior year period, while general and administrative expenses rose to $14.1 million from $6.4 million. The company held cash, cash equivalents, restricted cash, and investments of $243.2 million as of June 30, 2026, which management expects will fund operations into 2029. Clinically, enrollment continues in the Ntrust-1 and Ntrust-2 trials for NKX019 at a dose level of 4 billion cells per dose across multiple autoimmune indications, with initial clinical data expected to be presented at a medical conference in 2026. Nkarta is a clinical-stage biotechnology company developing engineered natural killer cell therapies to treat autoimmune diseases.